Frequency, Types and Predictors of Drug Therapy Problems Among Non-dialysis Chronic Kidney Disease Patients at a Tertiary Care Hospital in Pakistan

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2023 Apr 14

PMID 37058504

Authors

Muhammad Hayat

Nafees Ahmad

Syed Mohkumuddin

Syed Liaquat Ali Khan

Amer Hayat Khan

Noman Ul Haq

Naheed Haque

Amjad Khan

Affiliations

Soon will be listed here.

Abstract

Background: Drug therapy problems (DTPs) are common among patients suffering from chronic kidney disease (CKD). However, there is a lack of information about DTPs and its predictors among CKD patients from Pakistan.

Objectives: To evaluate the frequency, type and predictors of various types of DTPs among CKD patients at a tertiary-care hospital in Pakistan.

Methodology: This was a cross-sectional study carried out at Sandeman Provincial Hospital, Quetta between 1-11-2020 and 31-1-2021. It included 303 non-dialysis ambulatory patients of CKD-stage 3 and above. Cipolle et al., criterion was used for classifying the DTPs and a clinician at the study site checked the identified DTPs for accuracy. Data were analyzed by SPSS 23. Multivariate analysis was conducted to find the predictors of individual types of DTPs. A p-value <0.05 was considered statistically significant.

Results: The patients received a total of 2265 drugs with a median of eight drugs per patient (range: 3-15 drugs). A total of 576 DTPs were identified among 86.1% patients with a median of two DTPs (interquartile range 1-3) per patient. Dosage too high (53.5%) was the most common DTP followed by adverse drug reactions (ADRs) (50.5%) and need of additional drug therapy (37.6%). In multivariate analysis, patients' age of >40 years emerged as a predictor of unnecessary drug therapy and dosage too high. The odds of needing a different drug product was significantly high in patients with cardiovascular diseases (CVD) and diabetes mellitus (DM). The dosage too low had significant association with CVD. The risk of ADRs was significantly high in elderly patients (>60 years) and those with CVD. The presence of hypertension, DM and CKD stage-5 emerged as predictors of dosage too high.

Conclusion: This study revealed a high prevalence of DTPs among CKD patients. Targeted interventions in high risk patients may reduce the frequency of DTPs at the study site.

Citing Articles

Impact of pharmacist-led intervention for reducing drug-related problems and improving quality of life among chronic kidney disease patients: A randomized controlled trial.

Zafar R, Rehman I, Shah Y, Ming L, Goh K, Suleiman A PLoS One. 2025; 20(2):e0317734.

PMID: 39899613 PMC: 11790119. DOI: 10.1371/journal.pone.0317734.

References

Holm H, Bjerke K, Holst L, Mathiesen L . Use of renal risk drugs in patients with renal impairment. Int J Clin Pharm. 2015; 37(6):1136-42. DOI: 10.1007/s11096-015-0175-3. View

Barreto Lopes M, Tu C, Zee J, Guedes M, Pisoni R, Robinson B . A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps. Sci Rep. 2021; 11(1):1784. PMC: 7815803. DOI: 10.1038/s41598-020-79254-6. View

Ahmad N, Khan A, Khan I, Khan A, Atif M . Doctors' Knowledge of Hypertension Guidelines Recommendations Reflected in Their Practice. Int J Hypertens. 2018; 2018:8524063. PMC: 5867602. DOI: 10.1155/2018/8524063. View

Saheb Sharif-Askari F, Syed Sulaiman S, Sharif-Askari N, Al Sayed Hussain A . Development of an adverse drug reaction risk assessment score among hospitalized patients with chronic kidney disease. PLoS One. 2014; 9(4):e95991. PMC: 3995995. DOI: 10.1371/journal.pone.0095991. View

Alruqayb W, Price M, Paudyal V, Cox A . Drug-Related Problems in Hospitalised Patients with Chronic Kidney Disease: A Systematic Review. Drug Saf. 2021; 44(10):1041-1058. DOI: 10.1007/s40264-021-01099-3. View

Munar M, Singh H . Drug dosing adjustments in patients with chronic kidney disease. Am Fam Physician. 2007; 75(10):1487-96. View

Aburuz S, AlRashdan Y, Jarab A, Jaber D, Alawwa I . Evaluation of the impact of pharmaceutical care service on hospitalized patients with chronic kidney disease in Jordan. Int J Clin Pharm. 2013; 35(5):780-9. DOI: 10.1007/s11096-013-9806-8. View

Shastri S, Sarnak M . Cardiovascular disease and CKD: core curriculum 2010. Am J Kidney Dis. 2010; 56(2):399-417. DOI: 10.1053/j.ajkd.2010.03.019. View

Mason N . Polypharmacy and medication-related complications in the chronic kidney disease patient. Curr Opin Nephrol Hypertens. 2011; 20(5):492-7. DOI: 10.1097/MNH.0b013e328349c261. View

10.

Ahmad N, Hassan Y, Tangiisuran B, Meng O, Aziz N, Ahmad F . Guidelines adherence and hypertension control at a tertiary hospital in Malaysia. J Eval Clin Pract. 2012; 19(5):798-804. DOI: 10.1111/j.1365-2753.2012.01852.x. View

11.

Hung S, Chang Y, Liu J, Kuo K, Chen Y, Hsu C . Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes Endocrinol. 2015; 3(8):605-14. DOI: 10.1016/S2213-8587(15)00123-0. View

12.

Belaiche S, Romanet T, Allenet B, Calop J, Zaoui P . Identification of drug-related problems in ambulatory chronic kidney disease patients: a 6-month prospective study. J Nephrol. 2012; 25(5):782-8. DOI: 10.5301/jn.5000063. View

13.

Pillans P, Landsberg P, Fleming A, Fanning M, STURTEVANT J . Evaluation of dosage adjustment in patients with renal impairment. Intern Med J. 2003; 33(1-2):10-3. DOI: 10.1046/j.1445-5994.2003.00330.x. View

14.

Kovesdy C . Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022; 12(1):7-11. PMC: 9073222. DOI: 10.1016/j.kisu.2021.11.003. View

15.

Abdullah A, Ahmad N, Atif M, Khan S, Wahid A, Ahmad I . Treatment Outcomes of Childhood Tuberculosis in Three Districts of Balochistan, Pakistan: Findings from a Retrospective Cohort Study. J Trop Pediatr. 2020; 67(3). DOI: 10.1093/tropej/fmaa042. View

16.

Shahzadi A, Sonmez I, Kose C, Oktan B, Alagoz S, Sonmez H . The Prevalence of Potential Drug-Drug Interactions in CKD-A Retrospective Observational Study of Cerrahpasa Nephrology Unit. Medicina (Kaunas). 2022; 58(2). PMC: 8875967. DOI: 10.3390/medicina58020183. View

17.

Niriayo Y, Kumela K, Kassa T, Angamo M . Drug therapy problems and contributing factors in the management of heart failure patients in Jimma University Specialized Hospital, Southwest Ethiopia. PLoS One. 2018; 13(10):e0206120. PMC: 6198973. DOI: 10.1371/journal.pone.0206120. View

18.

Al Raiisi F, Stewart D, Fernandez-Llimos F, Salgado T, Mohamed M, Cunningham S . Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review. Int J Clin Pharm. 2019; 41(3):630-666. PMC: 6554252. DOI: 10.1007/s11096-019-00816-4. View

19.

Hasan M, Sutradhar I, Gupta R, Sarker M . Prevalence of chronic kidney disease in South Asia: a systematic review. BMC Nephrol. 2018; 19(1):291. PMC: 6199753. DOI: 10.1186/s12882-018-1072-5. View

20.

Ernst F, Grizzle A . Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001; 41(2):192-9. DOI: 10.1016/s1086-5802(16)31229-3. View